Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined haemoagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.

Abstract: A vaccine composition and method which is effective in preventing or ameliorating Avian Influenza Virus infection is set forth herein. The vaccine contains at least two inactivated strains of avian influenza virus, wherein the combined haemoagglutinin (HA) total is at least about 200 HA/dose of the vaccine composition, and wherein each of the strains presents at least about 128 HA/dose, and further wherein one of the strains has the same HA subtype as that of a challenge virus, and wherein at least one of the strains has a different NA subtype than the challenge virus.

Abstract: The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3? and 5?, further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.

Abstract: The vectors comprise a recombinant defective viral genome expressing at least one antigen suitable for the induction of systemic and secretory immune responses or an antibody conferring protection against an infectious agent. The defective viral genome comprises the genome of a parental virus having the viral replicase recognition signals located on ends 3′ and 5′, further comprising internal deletions, and wherein said defective viral genome depends on a helper virus for its replication and encapsidation. These vectors are suitable for the forming of a recombinant system comprising the aforesaid expression vector, and a helper virus. The system is suitable for the manufacture of mono- and polyvalent vaccines against infectious agents of different animal species, especially pigs, dogs and cats, and as expression vehicles for antibodies protective against infectious agents.

Abstract: The VP60 structural antigen or a fragment therof of rabbit hemorrhagic disease virus (RHDV) can be obtained in plants using a viral vector based on the plum pox virus (PPV), which includes a promoter, a recombinant DNA sequence including a cDNA to the genome of the PPV virus, full-length, and a DNA sequence which codes for the RHDV VP60 protein or a fragment thereof inserted between the nucleotide sequences coding the Nib and CP proteins of the PPV virus, and a cloning vehicle. The antigen obtained is capable of inducing protection in rabbits against a lethal challenge of RHDV, and can be used as a recombinant subunit vaccine against rabbit hemorrhagic disease virus.

Abstract: Recombinant proteins of the causative virus of porcine reproductive and respiratory syndrome (PRRS), corresponding to ORFs 2 to 7 of the PRRSV Spanish isolate (PRRS-Olot), have been produced in baculovirus expression system using Sf9 cell cultures as a permissive host. These recombinant proteins are suitable for the formulation of vaccines capable of efficaciously protecting porcine livestock from PRRS and for the preparation of diagnostic kits adequate for detection of anti-PRRSV antibodies as well as of PRRSV in a pig biological sample. This invention is of interest to Veterinary Medicine.